Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Tech health guideline

WHO Expands Global Contraception Guidelines

Analysis based on 6 articles · First reported Sep 23, 2026 · Last updated Sep 24, 2026

Sentiment
5
Attention
2
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The guidance expands the addressable market for contraceptive products, particularly long-acting implants, emergency contraceptives such as mifepristone, and future male contraceptives, benefiting pharmaceutical and medical device makers with approved products. It also signals a multi-year research and development pipeline opportunity, though near-term revenue effects are limited and the recommendation against quinestrol and caution on ormeloxifene could weigh on makers of those specific products.

pharmaceuticals healthcare medical devices

The World Health Organization published new guidelines on expanding contraceptive options, recommending a wider range of safe and effective methods and new ways to use existing ones. The guidance allows combined oral contraceptive pills to be taken for extended periods of up to six months or continuously for up to one year, and supports use of contraceptive implants for up to five years, which could reduce replacement procedures, clinic visits and costs. WHO also recommended mifepristone at doses of 10 to 50 mg as an additional emergency contraception option, taken as soon as possible and within five days of unprotected sex. The organization called for more research on ormeloxifene due to limited safety evidence and recommended against adding quinestrol-containing pills to national family planning programmes. WHO additionally published its first Target Product Profile for male contraceptive methods, setting out safety, effectiveness, acceptability and affordability criteria, and noted that several hormonal and non-hormonal male candidates are in advanced clinical trials, with new reversible male contraceptives potentially reaching the market within five to 10 years. The guidelines respond to an estimated 164 million women who want to delay or avoid pregnancy but are not using contraception.

70 World Health Organization expanded contraception guidance
65 World Health Organization published Target Product Profile
60 World Health Organization extended implant use
40 World Health Organization recommended against quinestrol
30 World Health Organization called for research
ngo
WHO is the central actor, issuing the expanded contraception guidelines, the mifepristone recommendation, the implant extension, the Target Product Profile for male contraceptives, and the calls for further research. The guidance strengthens its role in shaping global family planning policy and pharmaceutical development priorities.
Importance 100.0 Sentiment 10.0
per
As Director of WHO's Department of Sexual, Reproductive, Maternal, Child and Adolescent Health and Ageing, Pascale Allotey is the public face of the guidance, framing contraception choice as a gender equality issue and explaining the expanded options.
Importance 30.0 Sentiment 5.0
alliance
As WHO's parent organization, the United Nations is indirectly associated with the new global contraception guidance, reinforcing its health and development agenda.
Importance 20.0 Sentiment 5.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.